EIR Ventures
Venture capitalStockholm · Seed–Growth · 10 people tracked
Investment thesis
Eir Ventures invests in innovative medicine, backing Nordic life-science innovation intended to advance global health and improve millions of lives while delivering strong returns fund after fund. Its investment approach is built on a triad it applies to every portfolio company: transformative potential, excellence in execution, and scalability. The firm takes an active ownership role, creating companies and holding board seats, chairpersonships, and even CEO roles. It emphasizes translating rapidly evolving scientific innovations into business opportunities and patient benefits, and works with international syndication partners across the Nordics, Europe, and the US.
Source: firm website, verified Aug 3, 2026.
Team · 10 people
from the firm's website & public directories
What they invest in
from 17 of 24 portfolio companiesBiotech ×15Healthtech ×9Deep Tech ×5Medical Devices ×3AI & Machine Learning ×2Longevity ×2SaaS ×2Digital Health ×1
HQs:Sweden×6United States×2Denmark×1
Investments · 24 tracked
founders shown can be your intro pathBy year:2026 · 12023 · 12020 · 13 dated
Advancing potentially best-in-class therapeutics for myeloproliferative neoplasms.
BiotechCopenhagen, US
Christopher Cain(Director)Garrett Winslow(Executive Officer)Lori Firmani(Executive Officer)Peter Harwin(Director)Amit Munshi(Director)Hans T. Schambye(Executive Officer, Director)
Board seatStephan Christgau· per SEC Form D · $64.2M raise · filed Nov 2020
Co-investorsAccess BiotechnologyBay City Capital
Moleculent develops biological discovery and disease understanding tools for scientists.
AI & Machine LearningBiotechDeep Tech
Fredrik Roos(CTO & Co-founder)
Co-investorsARCH Venture Partners
Pretzel Therapeutics develops therapeutics targeting bioenergetic dysfunction and mitochondrial disease by addressing defects in mitochondrial DNA function and gene expression.
BiotechDeep TechHealthtechMedical Devices
Michal Minczuk(Co-Founder)Gabriel Martinez(Chief Scientific Officer & Co-Founder)Claes Gustafsson(Co-Founder)Maria Falkenberg(Co-Founder)Nils-Göran Larsson(Co-Founder)Jay Parrish(Chief Executive Officer & Chairman of the Board)in
Co-investorsARCH Venture PartnersCambridge Innovation CapitalGV (Google Ventures)HealthCap
ArgusEye develops LSPR-based biosensor systems for real-time monitoring and analytics of bioprocesses in biopharmaceutical development and manufacturing.
BiotechDeep TechHardware
Co-investorsVoima Ventures
Attgeno is a pharmaceutical company developing Supernitro, a therapy focused on the targeted delivery of nitric oxide to treat critically ill patients.
BiotechDigital HealthHealthtechMedical DevicesStockholm, SE
Lars E. Gustafsson(Co-founder (deceased))
BoardMagnus Persson(Chairman of the Board)
Co-investorsHadean Ventures
Swedish biopharmaceutical company developing novel potassium-competitive acid blockers for faster and more effective treatment of GERD.
Cinclus Pharma is a clinical-stage pharmaceutical company developing small molecules for gastric acid related diseases.
BiotechHealthtech
Christer Ahlberg(CEO)
Copenhagen-based oncology company developing treatments for acute myeloid leukemia and other cancer types based on University of Copenhagen research.
Entrilia is a cloud-native, API-first software platform for private capital and alternative asset operators, unifying fund accounting, reporting, investor portals, and data management into one system enhanced with agentic AI.
AI & Machine LearningFintechSaaS
Co-investorsWatertower Ventures Management, Llc
Damora Therapeutics is a biotechnology company developing subcutaneous biologics as targeted, disease-modifying treatments for patients with mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis.
BiotechMedical Devices
Jennifer Jarrett(Chief Executive Officer & Board Director)Sherwin Sattarzadeh(Chief Operating Officer)Becker Hewes(Chief Medical Officer)Garrett Winslow(General Counsel)Jim Baker(Chief Corporate Affairs Officer)Brian Burkavage(Senior Vice President, Finance)
Co-investorsHadean VenturesM VenturesSEED Capital DenmarkSunstone CapitalYsios CapitalMaverick Ventures+1 more
Gutcrine is a Danish biotech developing pharmabiotics derived from gut microbiome hormone synthesis, aimed at the prevention and treatment of cardio-metabolic disorders.
BiotechDeep TechHealthtechLongevityCopenhagen, DK
Oluf Pedersen(CSO & Co-founder)Yong Fan(COO & Co-founder)Tobias Horneman-Thielcke(CEO)in
Henlez is an early-stage biotech company working in the dermatology space.
BiotechHealthtech
Danish biotech developing non-opioid restorative treatments for chronic pain, hearing loss and sensory neuron disorders.
Co-investorsIndaco Venture Partners
Co-investorsMedical Incubator Japan K.K.
The page presents a biography of Dr.
Biotech
Co-investorsAvoro Capital AdvisorsKurma PartnersRA CapitalSamsara BioCapitalSunstone CapitalVivo Capital+2 more
Mitochondrial biology-focused biotech founded by leading academics in the field, developing novel therapeutics.
Purpose Pharma is a European pharmaceutical company that develops and commercializes products for rare diseases and specialty care in areas of high unmet medical need.
BiotechHealthtechStockholm, SE
Co-investorsIndustrifonden
Swedish digital health platform implementing value-based care monitoring for outpatient surgery to improve quality, patient satisfaction and healthcare efficiency.
The page is a domain listing/marketplace tool (ExpiredDomains.com) that aggregates expired and expiring domain names across many TLDs and lets users filter them by SEO authority, keywords, backlinks, and brand potential.
Marketing TechSaaS
SACRA Therapeutics is a drug discovery company developing therapeutics that target the RNA epitranscriptome, with a focus on oncology.
BiotechHealthtechLund, SE
Scenic Biotech develops disease-modifying therapies for patients with neurological and metabolic genetic disorders using its Cell-Seq discovery platform to identify modifier genes.
BiotechDeep TechHealthtech
Co-investorsBioMedPartnersOxford Science EnterprisesBioGeneration VenturesInkef
Gothenburg University spin-out developing first-in-class sortilin inhibitor therapies targeting metastasis and growth of aggressive cancers.
Strike Pharma develops a targeted lipid nanoparticle (LNP) delivery technology for in vivo CAR therapies aimed at autoimmune diseases and cancer.
BiotechLongevity
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 1
IPOs and acquisitions across the tracked portfolioDamora TherapeuticsNASDAQ: DMRA
Portfolio news
latest coverage across their companiesAttgeno · hadeanventures.com · May 27, 2026
Moleculent AB · finance.yahoo.com · Apr 30, 2026
IO Biotech · european-biotechnology.com · Apr 2, 2026
Pretzel Therapeutics · nasdaqprivatemarket.com · Aug 3, 2025
Frequently asked questions
- How many investments has EIR Ventures made?
- EIR Ventures has 24 tracked investments, including 1 dated in the last 24 months.
- What stage does EIR Ventures invest at?
- EIR Ventures invests at the Seed, Series A, Series B, Series C, Growth stages.
- What sectors does EIR Ventures focus on?
- EIR Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is EIR Ventures located?
- EIR Ventures is headquartered in Stockholm, SE.
- Does EIR Ventures lead rounds?
- Yes, EIR Ventures leads investment rounds.
- Who does EIR Ventures co-invest with?
- EIR Ventures most often shares deals with ARCH Venture Partners, Hadean Ventures, SEED Capital Denmark, among 20 tracked co-investors.
Media · Podcasts & interviews
featuring the team12: Investing in Biotech, with Lovisa Backemar, Principal at Eir Ventures
Investing & Other Stories Podcast · Lovisa Backemar
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.